Meeting
2020 ASCO Virtual Scientific Program
Concurrent and sequential chemoradiation therapy are associated with improved survival among unresected stage III non-small cell lung cancer patients in the United States.
Authors
Zhiyuan Zheng
American Cancer Society, Atlanta, GA
Zhiyuan Zheng , Ramesh Rengan , Jingxuan Zhao , Helmneh M. Sineshaw , Stephen G. Chun , Xuesong Han , Candice Yong , Brian S. Seal , Doris Makari , Charles B. Simone II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Outcomes
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7043)
DOI
10.1200/JCO.2020.38.15_suppl.7043
Abstract #
7043
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Survival outcomes in patients with chronic lymphocytic leukemia treated at academic centers.
First Author: Victoria Vardell
Poster
2021 ASCO Annual Meeting
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
First Author: David R. Spigel
Poster
2021 ASCO Annual Meeting
A comparative analysis of mortality between black and white stage III non–small cell lung cancer patients in the United States.
First Author: Elizabeth Blessing Elimimian
Poster
2020 ASCO Virtual Scientific Program
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation.
First Author: Josiah An